

December 9, 2022

To whom it may concern:

Company Name TOHO HOLDINGS CO., LTD.
Corporate Representative Atsushi Udoh, Representative Director, CEO
(Prime Market of Tokyo Stock Exchange Securities Code: 8129)

Contact: Makoto Kawamura, Corporate Officer and General Manager, Corporate Communications and Investor Relations Division
(TEL: 81-3-6838-2803)

Notice Regarding Launch of
1 Ingredient / 2 Products of Generic Drugs for KYOSOMIRAI PHARMA

TOHO HOLDINGS CO., LTD. (Headquarters: Tokyo; Representative Director, CEO: Atsushi Udoh) is pleased to announce that KYOSOMIRAI PHARMA CO., LTD. (Headquarters: Tokyo; President and Representative Director: Nobuaki Hosaka), the wholly-owned subsidiary involved in pharmaceuticals manufacture and sales business, has launched 1 ingredient / 2 products of generic drugs today on December 9, 2022 as below.

New products list

Class	Product Name	Original Brand Name
Selective serotonin reuptake inhibitor (SSRI)	Escitalopram OD Tablets 10mg/20mg "TOWA"	LEXAPRO®Tablets 10mg/20mg